세계의 인간 마이크로바이옴 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 용도별, 질환별, 기술별, 유형별, 지역별, 경쟁시장별(2020-2030년)
Human Microbiome Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product, By Application, By Disease, By Technology, By Type, By Region & Competition, 2020-2030F
상품코드:1785192
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
인간 마이크로바이옴 세계 시장 규모는 2024년에 6억 1,525만 달러로 평가되었고, 2030년에는 15억 2,405만 달러에 이르고, CAGR은 16.28%를 나타낼 전망입니다.
세계의 인간 마이크로바이옴 시장은 마이크로바이옴이 인간의 건강과 질병에 미치는 영향에 대한 과학적 인식 증가와 제약회사와 생명공학기업의 투자 증가로 큰 변모를 이루고 있습니다. 이 시장은 인체에 서식하는 수조의 미생물로 구성된 인간 미생물을 활용하거나 개조하여 의료 성과를 향상시키는 것을 목적으로 하는 진단제, 치료, 헬스케어 솔루션의 개발을 포함하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
6억 1,525만 달러
시장 규모 : 2030년
15억 2,405만 달러
CAGR 2025-2030년
16.28%
급성장 부문
프로바이오틱스
최대 시장
북미
시장 성장 촉진요인
암 치료에의 응용 확대
주요 시장 과제
마이크로바이옴의 기능에 대한 과학적 복잡성과 제한적인 이해
주요 시장 동향
개별화된 마이크로바이옴 치료로 이동
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 인간 마이크로바이옴 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
제품별(프리바이오틱스, 프로바이오틱스, 의료 식품, 보충제 등)
용도별(치료, 진단)
질환별(감염증, 내분비·대사 질환, 소화기 질환, 암, 기타)
기술별(유전체학, 단백질체학, 메타보로믹스)
유형별(FMT, 펩티드, 생바이오 의약품, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 인간 마이크로바이옴 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 인간 마이크로바이옴 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 인간 마이크로바이옴 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 인간 마이크로바이옴 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 인간 마이크로바이옴 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
제품 출시
합병과 인수
제13장 세계의 인간 마이크로바이옴 시장 : SWOT 분석
제14장 경쟁 구도
Enterome Bioscience SA
Yakult Honsha Co. Ltd.
4D Pharma
Evelo Biosciences
Seres Therapeutics Inc.
Vedanta Biosciences
Second Genome Inc.
Quantibiome
RebIoTix Inc.
Microbiome Therapeutics LLC
제15장 전략적 제안
제16장 기업 소개와 면책사항
SHW
영문 목차
영문목차
Global Human Microbiome market was valued at USD 615.25 Million in 2024 and is expected to reach USD 1524.05 Million by 2030 with a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 615.25 Million
Market Size 2030
USD 1524.05 Million
CAGR 2025-2030
16.28%
Fastest Growing Segment
Probiotics
Largest Market
North America
Key Market Drivers
Increased Application in Cancer Treatment
Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.
The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.
The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.
Key Market Challenges
Scientific Complexity and Limited Understanding of Microbiome Functions
One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome's structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for "healthy" microbiota.
This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.
The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.
This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.
Key Market Players
Enterome Bioscience SA
Yakult Honsha Co. Ltd.
4 D Pharma
Evelo Biosciences
Seres Therapeutics Inc.
Vedanta Biosciences
Second Genome Inc.
Quantibiome
Rebiotix Inc.
Microbiome Therapeutics LLC
Report Scope:
In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Human Microbiome Market, By Product:
Prebiotics
Probiotics
Medical Food
Supplements
Others
Human Microbiome Market, By Application:
Therapeutic
Diagnostic
Human Microbiome Market, By Disease:
Infectious Disease
Endocrine and Metabolic Disorders
Gastrointestinal Diseases
Cancer
Others
Human Microbiome Market, By Technology:
Genomics
Proteomics
Metabolomics
Human Microbiome Market, By Type:
FMT
Peptide
Live Biotherapeutic Product
Others
Human Microbiome Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.
Available Customizations:
Global Human Microbiome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Human Microbiome Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
5.2.2. By Application (Therapeutic, Diagnostic)
5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Human Microbiome Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease
6.2.4. By Technology
6.2.5. By Type
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Human Microbiome Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease
6.3.1.2.4. By Technology
6.3.1.2.5. By Type
6.3.2. Canada Human Microbiome Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease
6.3.2.2.4. By Technology
6.3.2.2.5. By Type
6.3.3. Mexico Human Microbiome Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease
6.3.3.2.4. By Technology
6.3.3.2.5. By Type
7. Europe Human Microbiome Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease
7.2.4. By Technology
7.2.5. By Type
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human Microbiome Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease
7.3.1.2.4. By Technology
7.3.1.2.5. By Type
7.3.2. United Kingdom Human Microbiome Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease
7.3.2.2.4. By Technology
7.3.2.2.5. By Type
7.3.3. Italy Human Microbiome Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease
7.3.3.2.4. By Technology
7.3.3.2.5. By Type
7.3.4. France Human Microbiome Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease
7.3.4.2.4. By Technology
7.3.4.2.5. By Type
7.3.5. Spain Human Microbiome Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease
7.3.5.2.4. By Technology
7.3.5.2.5. By Type
8. Asia-Pacific Human Microbiome Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease
8.2.4. By Technology
8.2.5. By Type
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human Microbiome Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease
8.3.1.2.4. By Technology
8.3.1.2.5. By Type
8.3.2. India Human Microbiome Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease
8.3.2.2.4. By Technology
8.3.2.2.5. By Type
8.3.3. Japan Human Microbiome Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease
8.3.3.2.4. By Technology
8.3.3.2.5. By Type
8.3.4. South Korea Human Microbiome Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease
8.3.4.2.4. By Technology
8.3.4.2.5. By Type
8.3.5. Australia Human Microbiome Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease
8.3.5.2.4. By Technology
8.3.5.2.5. By Type
9. South America Human Microbiome Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease
9.2.4. By Technology
9.2.5. By Type
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human Microbiome Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease
9.3.1.2.4. By Technology
9.3.1.2.5. By Type
9.3.2. Argentina Human Microbiome Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease
9.3.2.2.4. By Technology
9.3.2.2.5. By Type
9.3.3. Colombia Human Microbiome Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease
9.3.3.2.4. By Technology
9.3.3.2.5. By Type
10. Middle East and Africa Human Microbiome Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease
10.2.4. By Technology
10.2.5. By Type
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Human Microbiome Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease
10.3.1.2.4. By Technology
10.3.1.2.5. By Type
10.3.2. Saudi Arabia Human Microbiome Market Outlook
